A selection of major announcements

1. Great Wall Motor sold 112,500 units in December, an increase of 45.27% year-on-year

$GWMOTOR (02333.HK)$According to the announcement, in December 2023, automobile sales were 112,500 units, up 45.27% year on year; automobile production was 98,400 units, up 10.75% year on year. In 2023, automobile sales were 1.23,700 units, up 15.29% year on year; automobile production was 1.265,400 units, up 14.79% year on year. In December, 29,858 new energy vehicles were sold, and a total of 26,2003 units were sold in January-December.

2. China Railway Construction recently won a total of 73.298 billion yuan of major projects

$CHINA RAIL CONS (01186.HK)$An announcement was issued. Recently, the company won bids for several major projects with a total amount of 73.298 billion yuan, accounting for 6.69% of the company's 2022 audited revenue.

3. C&D International Group: The cumulative contract sales amount in 2023 was about 137.96 billion yuan, an increase of 13.5% over the previous year

$C&D INTL GROUP (01908.HK)$An announcement was issued. For the year ended December 31, 2023, the Group, together with its joint ventures and associated companies, achieved a cumulative contract sales amount of about RMB 137.96 billion, and the total contract sales floor area belonging to the company's shareholders' equity was about RMB 6.664 million square meters, an increase of about 13.5% and 9.3% respectively over the previous year.

4. Kingsley Biotechnology: Legendary Biotech and Novartis completed a global licensing agreement

$GENSCRIPT BIO (01548.HK)$An announcement was issued regarding the signing of an exclusive global license agreement between Legendary Biotech and Novartis. Legend Biotechnology Co., Ltd. (a non-wholly-owned subsidiary of the company, its shares are listed on the NASDAQ Global Select Market in the US in the form of American Depositary Shares) has announced that on January 3, 2024 (New York time), Legend has completed a license agreement with Novartis for several chimeric antigen receptor T cell (CAR-T) therapies targeting delta-like ligand protein 3 (DLL3), including Legend's existing proprietary CAR-T cell therapy candidate “LB2102.” Receive a $100 million cash advance payment under the license agreement.

Increase or decrease holdings

$MEITUAN-W (03690.HK)$Acquired 265.36,800 shares from J.P. Morgan

$XPENG-W (09868.HK)$Acquired 10.592 million shares from J.P. Morgan Chase

Operational data

$AGILE GROUP (03383.HK)$The total pre-sale amount for 2023 was 45.30 billion yuan

$ZHENRO PPT (06158.HK)$The cumulative contract sales amount in 2023 is approximately $15.380 billion

$SHINSUN HOLD GP (02599.HK)$The total contract sales volume belonging to the group in 2023 is about 17.911 billion yuan

$JINGRUI HLDGS (01862.HK)$: Cumulative contract sales in 2023: $3,787 billion

Pharmaceutical Innovation

$IMMUNOTECH-B (06978.HK)$: First patient enrolled in phase II clinical trial of CAR-T-19 injection

$CRYOFOCUS-B (06922.HK)$Passed the GMP review by the Shanghai Drug Administration

$CLOUDR (09955.HK)$: Apply for medical device registration for CloudT-01

$SINO BIOPHARM (01177.HK)$: “Everolimus tablets” challenged patent success and achieved the first imitation

Equity incentives

$ASCLETIS-B (01672.HK)$Grant of 6.3 million share options

Repurchase cancellation

$TENCENT (00700.HK)$On January 3, it spent HK$1.02 billion to repurchase 3.36 million shares

$HSBC HOLDINGS (00005.HK)$On January 2, it cost HK$167 million to repurchase 2,657,200 shares

$DFZQ (03958.HK)$: A total of 334.886,400 A-shares have been repurchased through centralized bidding transactions

$AIA (01299.HK)$On January 3, it cost HK$135 million to repurchase 2,079,600 shares

$XIAOMI-W (01810.HK)$On January 3, 3.3 million shares were repurchased at HK$49.21 million

$CONCH CEMENT (00914.HK)$: A total of 15.65 million A-shares have been repurchased

$KINGSOFT (03888.HK)$On January 3, 868,600 shares were repurchased at HK$1999 million

$YUM CHINA (09987.HK)$On January 2, $2.4 million was spent to buy back 56,600 shares

$BEKE-W (02423.HK)$On January 2, it cost 2 million US dollars to buy back 382,000 shares

$SKYWORTH GROUP (00751.HK)$On January 3, it cost HK$8.952 million to buy back 3 million shares

$GREENTOWN SER (02869.HK)$1.696 million shares were repurchased at HK$4.8838 million on January 3

$KUAISHOU-W (01024.HK)$On January 3, it cost HK$4.27 million to buy back 84,000 shares

edit/ruby